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Abstract
Multiple myeloma (MM) is a cancer of antibody-making plasma cells. It frequently harbors alterations in DNA and
chromosome copy numbers, and can be divided into two major subtypes, hyperdiploid (HMM) and non-hyperdiploid
multiple myeloma (NHMM). The two subtypes have different survival prognosis, possibly due to different but converging
paths to oncogenesis. Existing methods for identifying the two subtypes are fluorescence in situ hybridization (FISH) and
copy number microarrays, with increased cost and sample requirements. We hypothesize that chromosome alterations have
their imprint in gene expression through dosage effect. Using five MM expression datasets that have HMM status measured
by FISH and copy number microarrays, we have developed and validated a K-nearest-neighbor method to classify MM into
HMM and NHMM based on gene expression profiles. Classification accuracy for test datasets ranges from 0.83 to 0.88. This
classification will enable researchers to study differences and commonalities of the two MM subtypes in disease biology and
prognosis using expression datasets without need for additional subtype measurements. Our study also supports the
advantages of using cancer specific characteristics in feature design and pooling multiple rounds of classification results to
improve accuracy. We provide R source code and processed datasets at www.ChengLiLab.org/software.
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Introduction
Multiple myeloma (MM) is a plasma cell malignancy charac-
terized by complex and heterogeneous cytogenetic abnormalities
[1]. In the U.S., multiple myeloma is the second most common
hematological malignancy and constitutes 1% of all cancers [2].
Aneuploidy, defined as copy number changes of chromosomes or
regions, is a common feature of many human cancers including
MM [3]. Common chromosome amplification and deletion events
can be used as a feature to subdivide multiple myeloma into two
subtypes. Using fluorescence in situ hybridization (FISH), multiple
myeloma is divided into hyperdiploid multiple myeloma (HMM)
and non-hyperdiploid multiple myeloma (NHMM) [4,5]. Approx-
imately 55–60% of patients have the hyperdiploid karyotype, with
trisomies of eight specific chromosomes, including chromosome 3,
5, 7, 9, 11, 15, 19 and 21 [6,7]. The remaining cases form the non-
hyperdiploid group, frequently involving translocations and
hemizygous deletion of chromosome 13.
The two MM subtypes have different prognosis and survival
outcome. Patients with hyperdiploid multiple myeloma tend to
have a better prognosis than those with non-hyperdiploid subtype
[4,8,9]. Therefore, cytogenetic and genomics based prognosis
models should use the subtype status as a covariate to help uncover
novel and independent factors for prognosis and drug response.
Furthermore, the two MM subtypes may be driven by different
but overlapping paths to oncogenesis. As genomics profiling of
RNA and DNA is increasingly used in myeloma studies, with the
subtype status of patient samples we can perform meta-analysis of
genomics profiling datasets to study common and specific
pathways dysregulated in the two subtypes and corresponding
drug candidates.
However, most genomics profiling myeloma studies do not have
HMM status measured. The existing standard method for
distinguishing the two subtypes is FISH, which measures a few
chromosomes’ trisomy status and can be inaccurate for determin-
ing the hyperdiploidy status of cancer samples. Using array
comparative genomics hybridization (aCGH) or SNP arrays to
detect genome-wide copy number changes can also readily identify
the two major subtypes [10], but paired copy number and
PLOS ONE | www.plosone.org 1 March 2013 | Volume 8 | Issue 3 | e58809expression datasets are few. In this study, we hypothesize that
chromosome alterations have their imprint in gene expression
through dosage effect, and aim to build a robust, cross-platform
method to classify multiple myeloma subtypes using gene
expression profiles. The resulting MM subtype status will greatly
help the analysis of existing and future myeloma profiling datasets
in better understanding the commonalities and differences of
disease biology and prognosis in HMM and NHMM subtypes.
Materials and Methods
Gene expression profiles
GSE6477, GSE19784, GSE6401 are 3 gene expression
profiling datasets from GEO (http://www.ncbi.nlm.nih.gov/
geo/) [11–13]. All of them have been separated into HMM and
NHMM with FISH, and the exact method are in the
corresponding papers. Among these data, GSE6477 and
GSE6401 are of the same array platform (HG-U133A) while
GSE19784 is different (HG-U133_Plus2). To test classification
accuracy using copy number-based HMM status, we use
GSE29023 with paired expression and array CGH profiling
[14], and GSE12896 and GSE39754 with paired expression and
SNP array profiling [10].
Training, validation and test datasets
We use GSE6477 and GSE19784 as training data and
validation data to build the method and select parameters, and
use GSE6401 as test data to test the accuracy of method.
GSE6477 was one of the early datasets about multiple myeloma
Figure 1. A general flowchart of the classification analysis steps.
doi:10.1371/journal.pone.0058809.g001
Figure 2. Scatterplot of trisomy and nontrisomy chromosome means of GSE6477 samples. Each point represents a patient sample. ‘TC
mean’ on X-axis is the average scaled expression values for the genes on the 8 trisomy chromosomes. ‘NTC mean’ on Y-axis is the average scaled
expression values for the genes on nontrisomy chromosomes. The light purple circles are HMM samples and the dark purple circles are NHMM
samples determined by FISH. The green circle is the left-out sample to be classified.
doi:10.1371/journal.pone.0058809.g002
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doi:10.1371/journal.pone.0058809.g003
Figure 4. Scatterplot of trisomy and nontrisomy chromosome means of both GSE6477 and GSE19784 samples. See Figure 2 legend for
details. The top right part are GSE19784 samples separated into two FISH subtypes by color. The two datasets are far from each other.
doi:10.1371/journal.pone.0058809.g004
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same number of two subtypes (70 HMM and 70 NHMM). We use
GSE19784 to improve the method for cross platform/dataset
classification and as validation data to minimize over-fitting. The
rest datasets are used for testing the classification accuracy.
Microarray data processing
All gene expression profile analysis procedures were performed
using R (version 2.13.1). Package ‘affy’ was used for primary
process [15]. Custom CDF files were used for R 2.13 (http://
brainarray.mbni.med.umich.edu/). The probe level data was
converted to expression values using the BioConductor project
with the Robust Multi-Array average (RMA) procedure, in which
perfect match intensities were background adjusted, quantile-
quantile normalized, and log2-transformed [16,17]. R package
‘kknn’ was used for KNN and KKNN classification (http://cran.r-
project.org/web/packages/kknn/).
Definition of trisomy chromosomes
Based on frequent trisomy status of eight chromosomes in
HMM, we separate genes into two groups: trisomy-chromosome
genes (genes on chromosomes 3, 5, 7, 9, 11, 15, 19 and 21) and
nontrisomy-chromosome genes (genes on the rest chromosomes)
[6]. We use UCSC hg19 RefSeq gene table as reference (http://
genome.ucsc.edu/).
Determine HMM status from copy number microarray
data
We used two test datasets with paired copy number microarray
samples as gold standard for HMM status. In GSE29023, for each
sample we computed the ratio between the median copy number
of the trisomy chromosomes and that of the non-trisomy
chromosomes, and plotted the histogram of the ratios. We
expected this ratio to be around 1.5 (3 copy/2 copy) for HMM
samples and 1 (2 copy/2 copy) for NHMM samples, since HMM
samples usually have 3 copies in most of the 8 trisomy
chromosomes, but NHMM samples have 2 copies in these
chromosomes. With the expectation that the patients should be
separated into two groups, we observed the histogram and chose
the boundary 1.125 as half-way between the two peaks in the
distribution. The fact that we didn’t observe a cutoff midway
between 1 and 1.5 could be due to sample normalization during
microarray analysis, where the overall signal distribution in one
sample is adjusted to be similar across all samples. This may lead
to a downward shifting of all signals in a HMM sample, where 8
chromosomes are usually in trisomy. A cutoff of 1.10 or 1.15 is also
possible from this histogram, but this leads to only 3 samples to be
assigned differently and a difference in accuracy of ,2.6% (3/115
of samples in GSE29023).
In GSE12896, we plotted the distribution of the median copy
number of the trisomy chromosomes and expected the median to
be around 3 for HMM and around 2 for NHMM. We observed
the corresponding two peaks, although the HMM samples peak at
2.6 due to possible normalization effect as above. We chose the
Figure 5. Scatterplot of adjusted trisomy and nontrisomy chromosome means of both GSE6477 and GSE19784 samples. Adjusting
and overlapping the distributions of GSE6477 and GSE19784 makes classification more accurate. For all the sample points in a dataset from Figure 4,
we shift their locations by the same amount, so the center of the samples points locates at (0, 0).
doi:10.1371/journal.pone.0058809.g005
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HMM and NHMM samples from the copy number data.
Results
Develop classification method for HMM status by cross-
validation
We used K-nearest neighbor (KNN) method and leave-one-out
cross-validation (LOOCV) to develop the classification method for
HMM status. Based on this method, we leave one sample out of
GSE6477 and use the remaining data as training samples for
fitting the classification model. A list of genes differentially
expressed between HMM and NHMM of the training samples
are used to construct a two-dimensional feature vector to classify
the left-out sample. The overall classification accuracy from cross-
validation is used to select the optimal model parameters. An
overview of the procedure is in Figure 1 and the detailed steps are
as follows.
First, using GES6477, we left one sample out and used the rest
139 samples to perform Student’s t-test between HMM and
NHMM using each gene’s expression data. Controlling for FDR
(False Discovery Rate) that is less than 0.01, we obtained a list of
genes that are differentially expressed between HMM and
NHMM. We subdivided these genes into trisomy-chromosome
genes (TC genes) and nontrisomy-chromosome genes (NTC genes)
according whether a gene belongs to trisomy chromosomes or
nontrisomy chromosomes (see Methods). Table S1 lists the
intersection genes used in the 140 leave-one-out classification
models.
Next, we standardized GSE6477 to make the mean of each
sample’s expression values of all genes to be 0 and the variance of
each sample to be 1, and got the GSE6477_scale data. This step is
necessary for cross-platform/dataset classification in the next
section. Then, for each sample in the training and validation sets
of GSE6477_scale, we computed the mean expression of the TC
genes and NTC genes, respectively, and denote the two means as
TC mean and NTC mean. Figure 2 shows that when plotting
NTC mean vs. TC mean for all the samples, HMM and NHMM
samples largely separate.
Last, we used TC mean and NTC means as the feature values
of each sample to perform K-nearest neighbor algorithm (KNN) to
classify the left-out sample using the 139 training samples. KNN is
a method for classifying objects based on closest training examples
in the feature space, which is our core algorithm for classification
[18,19]. The main parameter of KNN is the k value, the number
of neighbors considered [18]. We used different k parameters from
1 to 69 to explore the best k value for classification. For a given k
value, we performed leave-one-out cross-validation to classify
every sample, and compared the classified subtypes to the original
FISH-based subtypes of all samples to assess the overall
classification accuracy. Figure 3 shows the classification accuracy
with various value of k from 1 to 69 for GSE6477 cross-validation
results. When the k value is more than 2, the accuracy of
classification is more than 80%.
Figure 6. Scatterplot of adjusted trisomy and nontrisomy chromosome means of GSE6401. The green triangles indicate misclassified
samples. Most of them locate at the boundary area between the samples of two FISH subtypes.
doi:10.1371/journal.pone.0058809.g006
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We next used GSE19784 to check the applicability of the
classification method developed from GSE6477 when applied to
an independent dataset and patient cohort. GSE19784 uses a
different array platform, comes from a different research study and
has more MM samples (201 MM samples with FISH status).
These factors may affect the accuracy of cross-dataset classifica-
tion. To minimize platform and batch differences between the two
datasets, we also standardized GSE19784 to make the mean
expression values of all genes in each sample to be 0 and the
variance of each sample to be 1, and obtained the GSE19784_s-
cale data. To apply a classification model from one cross-
validation run of GSE6477 (Figure 2), we retrieved the
corresponding differential expressed gene list from the classifica-
tion model and computed TC mean and NTC mean for every
sample of GSE19784_scale. However, the distribution of the two
data sets was far in distance, making the KNN classification
challenging and less accurate across datasets (Figure 4).
On a closer look, we observed that the relative locations and
overall shape of HMM and NHMM samples within a dataset are
similar for the two datasets (Figure 4). In order to adjust for dataset
specific characteristics, we overlaid the two datasets’ distributions
(Figure 5). Specifically, we shifted the locations of all the sample
points in a dataset in the TC mean vs. NTC mean plot, so that all
the sample points in the dataset have the 0 average in both X-axis
and Y-axis values. As the result, both datasets have their data
points centered at (0, 0) and their overall distributions are
overlapping (Figure 5), facilitating KNN classification across array
platform and datasets.
Last, we used the adjusted TC mean and NTC mean as sample
features to classify samples in GSE19784_scale using models
trained from GSE6477. We classified each sample in GSE19784
140 times using each of the leave-one-out cross-validation models
from GSE6477. The subtype classified as the majority of 140 times
is the final classified subtype of the sample. We then compared the
classified subtype of GSE19784 samples to their FISH-based
subtype to check the cross-dataset classification accuracy. Figure 3
shows that for k.8, we obtained classification accuracy .82%.
Test the classification method using independent
datasets with FISH and copy number-based HMM status
Using the classification results of GSE6477 (within-dataset
cross-validation) and GSE19784 (cross-dataset classification), we
explored values of k from 1 to 69 that resulted in high classification
accuracy (Figure 3). We selected k=16 to classify three
independent test datasets, GSE6401, GSE29023 and GSE39754.
We performed similar procedure as above, using the GSE6477-
trained models to classify GSE6401, and obtained a cross-dataset
classification accuracy of 0.88 when compared to FISH (Figure 6).
We also tested the classification method using two MM
expression datasets with paired copy-number profiling samples.
The first is GSE29023, consisting of paired gene expression and
Figure 7. Determine the copy number-based HMM status in GSE29023. For each sample, the ratio between the median array-CGH based
copy numbers of the trisomy chromosomes and that of the non-trisomy chromosomes is computed. See Methods for details. With the expectation
that the patients should be separated into two groups, we observed the histogram and chose the boundary 1.125 as half-way between the two
peaks in the distribution.
doi:10.1371/journal.pone.0058809.g007
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genomic copy number variations at a high resolution. We first
utilized the CGH data to compute the ratio between the median
copy number of trisomy chromosomes and of nontrisomy
chromosomes for each patient. For HMM samples we expect
higher ratios because they tend have three copies in the trisomy
chromosomes. The histogram of the ratios shows a division of
samples (Figure 7), and we set the cutoff as 1.125 to call real HMM
status based on copy numbers. Last, we applied the expression-
based classification method to call HMM status, which agreed
with the copy number-based HMM status at a accuracy of 0.835
(96/115).
The second MM dataset is GSE12896 and GSE39754 with 170
paired gene expression and SNP array profiling samples [10]. The
survival outcome of the patients is also available. We used the
median copy number of trisomy chromosomes in each sample to
call real HMM status of the samples (Figure 8). The expression-
classified subtype agreed with copy number-based HMM status at
a accuracy of 0.876 (149/170). Furthermore, the expression-
classified subtype separated the patients into two groups of
significantly different survival (Figure 9, p-value=0.0208), agree-
ing with known survival differences between HMM and NHMM
groups [4,8,9].
Pool multiple rounds of classification results to improve
accuracy
When we applied our classification method trained from
GSE6477 to other datasets, we classified each new sample 140
times using the 140 cross-validation models that built from
GSE6477. In the above we assigned the final classified subtype
using majority voting from the 140 classified subtype calls. We also
computed a confidence score for each sample as the proportion of
140 classified subtype calls for the winning majority. When we
classified only those samples with confidence score .0.9, the
classification accuracy for GSE39754 improved from 0.876 to
0.913 (147/161). This is due to that in the 9 unclassified samples
with confidence score ,0.9, 7 were misclassified previously. For
GSE6401, If we only classified samples whose confidence score is
more than 0.9, the accuracy increased from 0.88 (66/75) to 0.93
(62/67).
Discussion
Multiple myeloma is a malignant cancer of bone marrow
plasma cells. Researchers are making progress in diagnosing and
treating multiple myeloma in innovative ways; however, it cannot
be fully cured by current treatment regimes. The two main
aneuploidy-based subtypes of multiple myeloma, HMM and
NHMM, correspond to different survival prognosis and potential
underlying different pathogenic pathways and altered regulatory
Figure 8. Determine the copy number-based HMM status in GSE12896. The median copy number of SNPs in trisomy chromosomes is
computed for each sample. The histogram suggests a cutoff of 2.3 to determine HMM status (median copy .2.3 for HMM samples). See Methods for
details.
doi:10.1371/journal.pone.0058809.g008
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measure HMM status, we have developed an expression-based
method to classify HMM status of patients with high accuracy
across datasets and array platforms. Compared with FISH and
copy number based HMM status, the test accuracy in three
independent datasets ranges from 0.83 and 0.88. Our method
opens up the opportunity for meta-analysis of many MM
expression datasets for the disease biology of HMM and NHMM
subtypes, and for incorporating HMM status as a covariate in
genomics-based survival prognosis models. The lessons we learned
in this study, such as using cancer specific characteristics in feature
design and pooling multiple rounds of classification results to
improve accuracy, are applicable to similar genomics-based
classification. We also provide R package and processed datasets
publicly at www.ChengLiLab.org/software.
Use cancer-specific characteristics in classification
features
Inferring chromosome abnormalities using gene expression
profiles can help predict clinical outcomes and identify causal
genomic alterations [14,20,21]. In a recent myeloma study, Zhou
and colleagues reported cytogenetic abnormalities classification
based on gene expression profiles with accuracy up to 0.89 [14].
Similar to their study, our classification method also based on
expression data and considered special genes. Due to different
purposes, Zhou et al. emphasized copy number-sensitive genes,
while we focused on genes in trisomy and non-trisomy chromo-
somes.
Importantly, we found that the carefully selected gene features
considering trisomy and non-trisomy chromosomes resulted in
more classification power than using the whole list of differentially
expressed genes between the two subtypes. We decided that the
adjusted TC mean and NTC mean are good features for cross-
dataset KNN classification (Figure 5). The classification accuracy
is higher than when we use all differential expressed genes as
features to classify new samples (Table 1). The reason lies in that
we took biological features of multiple myeloma into consider-
ation. Abundant copy number changes of whole and partial
chromosomes are a characteristic feature of multiple myeloma and
its two subtypes (Figure 10), which lead to dosage effect of many
expressed genes located in these chromosome regions. Such
dosage alterations affect global gene expression more strongly than
platform differences and batch effect do. By using two summa-
rizing features (TC mean and NTC mean) to capture these
subtype specific characteristics, such as 8 trisomy chromosomes in
HMM and chromosome 13 deletion in NHMM, we achieved
better classification accuracy than not considering these charac-
teristics.
Figure 9. Survival difference between expression-classified HMM and NHMM groups in GSE39754. HMM patients (red) classified by our
method have a better overall survival than the NHMM patients (blue). The log-rank test p-value is 0.0208.
doi:10.1371/journal.pone.0058809.g009
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improvements
Although we developed an effective method to classify multiple
myeloma subtypes, we did not achieve 100% accuracy. There are
both biological causes and analytical causes for misclassified
samples. Biologically, multiple myeloma genome is not strictly
altered following main HMM and NHMM characteristics. Some
MM samples could have both trisomy chromosomes and deletion
of chromosome 13 (Figure 10, samples in the middle between
HMM and NHMM clusters). These samples may possess
expression profiles that partially resemble to both HMM and
NHMM, and therefore lie in the boundary between the two
Table 1. Comparison of accuracy between standard KNN
classification using all differentially expressed genes and the
two-feature method (k=16).
Dataset Standard KNN classification
Two-feature KNN
classification
GSE6477 0.85 0.86
GSE19784 0.57 0.83
GSE6401 0.71 0.88
doi:10.1371/journal.pone.0058809.t001
Figure 10. Clustering MM samples in GSE12896 by genome-wide copy numbers. 170 MM samples are clustered from left to right based on
their similarities in copy number alterations. SNPs are ordered by chromosome positions from top to bottom. The color scale on the bottom indicates
log2 ratios relative to two copies. Blue color indicates copy number loss, white color indicates copy number close to normal, and red color indicates
copy number gains. The horizontal red and blue bars on the top indicate sample groups of HMM (red) and NHMM (blue) as determined from Figure 8.
Black vertical bars on the top indicate misclassified samples.
doi:10.1371/journal.pone.0058809.g010
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triangle in Figure 6 and Figure 11), rendering KNN classifiers
unable to call their HMM status with high confidence. We also
notice that a portion of misclassified samples in the dataset
GSE12896/GSE39754 are NHMM samples with deletion of both
chromosome 1 and 4 (Figure 10, misclassified samples on the left,
indicated by black vertical bars). These observations point to
directions to further improving the classification method based on
biological features of interest.
Another biological cause is inaccuracy of FISH-based HMM
status, which may probe only a few chromosomes to determine
hyperdiploidy. A hypothetical example is a tetraploid sample with
4 copies for most chromosomes. Its transcriptomic profiles may be
similar to NHMM due to equal copy numbers of most genes, but
FISH could report it as hyperdiploidy.
Analytically, as we used all sample points to adjust the center of
a dataset’s sample points in the NTC mean vs. TC mean plot
(Figure 5), the proportion between real HMM and NHMM
samples could affect this adjustment. For example, if a patient
cohort contained all HMM samples, we would have classified half
of the samples as NHMM since this is the subtype proportion in
the training dataset GSE6477. Although HMM proportion is
around 55–60% in a typical MM cohort [7], in the 5 datasets we
used, the HMM proportion ranges between 39% and 56% as
measured by FISH or copy number microarrays (GSE6477: 70/
140, 50%; GSE19784: 113/201, 56%; GSE6401: 37/75, 49%;
GSE29023: 45/115, 39%; GSE39754: 77/170, 45%). A future
improvement in this regard is to iteratively estimate the proportion
of HMM samples during classification.
We have also compared to two other classification methods,
support vector machine (SVM) and weighted k-nearest neighbors
Figure 11. Scatterplot of adjusted trisomy and nontrisomy chromosome means of GSE39754. The green triangles indicate misclassified
samples. Most of them locate at the boundary area between the samples of two copy-number based subtypes.
doi:10.1371/journal.pone.0058809.g011
Table 2. Classification accuracy for original and modified GSE6401 sample sets.
HMM/NHMM 37/23 37/28 37/33 37/38 (original data) 32/38 27/38 22/38 19/38
% of HMM Method 62% 57% 53% 49% 46% 42% 37% 33%
KKNN 0.84 0.87 0.87 0.88 0.86 0.84 0.85 0.80
KNN 0.85 0.86 0.88 0.88 0.86 0.78 0.77 0.71
TC and NTC means are used as features. The kernel ‘optimal’ and ‘rectangular’ of KKNN is used.
doi:10.1371/journal.pone.0058809.t002
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data in the same way as the original KNN classification, and
k=16 is used for both KNN and KKNN. SVM classifies only one
more sample correctly than KNN (the accuracy increases from
0.88 to 0.89), and KKNN achieves the same accuracy as KNN.
Due to potential better performance of KKNN for unbalanced
datasets, we removed various number of HMM or NHMM
samples from GSE6401 to create unbalanced datasets, and used
KKNN to classify HMM status. Table 2 shows that for both KNN
and KKNN, the classification accuracy decreases for unbalanced
datasets, but KKNN classifies some unbalanced datasets at up to
9% better accuracy than KNN. Therefore the merit of using
KKNN for unbalanced datasets is justified in this setting.
Computing a confidence score by pooling results of multiple
rounds of classification could improve the accuracy, if samples
with low confidence score tend to be misclassified. In our analysis
of GSE39754 and GSE6401, not classifying samples with
confidence score ,0.9 improved classification accuracy from
0.876 to 0.913 and from 0.88 to 0.93, respectively. In the TC
mean vs. NTC mean plots (Figure 6 and Figure 11), most samples
that were misclassified are located near the boundary between the
two subtypes. These samples tend to be classified into either
subtype by multiple KNNs and therefore have lower confidence
scores. Some misclassified samples do not follow clear HMM or
NHMM copy number patterns (Figure 10, samples in the middle,
indicated by black vertical bars). Future studies will better define
smaller genomics subtypes other than HMM and NHMM, such as
those having few chromosomal alterations and those caused by
chromothripsis [22].
Supporting Information
Table S1 The 675 genes that are intersection gene
features among the 140 leave-one-out models of the
training dataset GSE6477. Chro Type: TC: Trisomy
chromosomes, NTC: Non-trisomy chromosomes. FDR: the
median FDR of all comparisons in the 140 models. HMM.Mean
and NHMM.Mean are the mean value of the scaled gene
expression in HMM and NHMM samples, respectively.
(XLS)
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